AT1-receptor blockade in experimental myocardial ischaemia/reperfusion

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue SUPPL. 1, 2001, Pages

  Schulz, Rainer ^a   Heusch, Gerd ^a,b  

^a Zentrum fur Innere Medizin   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

AT1 receptor; AT2 receptor; Myocardial ischaemia; Renin angiotensin aldosterone system; Reperfusion

Indexed keywords

EID: 0345893897     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/14703203010020012401     Document Type: Review

References (77)

1. Linder C, Heusch G: ACE inhibitors for the treatment of myocardial ischemia? Cardiovasc Drugs Ther 1990;4:1375-84.
2. Lindpaintner K, Wilhelm MJ, Jin M et al. Tissue reninangiotensin systems: Focus on the heart. J Hypertens 1987;5 (suppl 2):S33-S38.
3. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69:475-82.
4. Danser AHJ, Saris JJ, Schuijt MP, van Kats JP: Is there a local renin-angiotensin system in the heart? Cardiovasc Res 1999;44:252-65.
5. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40-8.
6. McAlpine HM, Cobbe SM. Neuroendocrine changes in acute myocardial infarction. Am J Med 1988;84 (suppl 3A):61-6
7. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 1993;27: 334-40.
8. Balcells E, Meng QC, Johnson Jr. WH, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;42:H1769-H1774.
9. Hollenberg NK. Implications of species difference for clinical investigation. Studies on the renin-angiotensin system. Hypertension 2000;35 [part 2]:150-4.
10. Baumgarten CR, Linz WL, Kunkel G, Schölkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 1993;108:293-5.
11. Timmermans PBMWM, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
12. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000;97:931-6.
13. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993;268:24539-42.
14. Scheuer DA, Perrone MH. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 1993;33:R917-R923.
15. Akishita M, Yamada H, Dzau VJ, Horiuchi M. Increased vasoconstrictor response of the mouse lacking angiotensin II Type 2 receptor. Biochem Biophys Res Commun 1999;261:345-9.
16. Hunley TE, Tamura M, Stoneking BJ et al. The angiotensin type II receptor tonically inhibits angiotensin-converting enzyme in AT2 null mutant mice. Kidney Int 2000;57:570-7.
17. Stoll M, Steckelings UM, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-7.
18. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11(Suppl 2):S19-S25.
19. Liu Y-H, Yang X-P, Sharov VG, Nass O, Sabbah HH, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-35.
20. Wiemer G, Schölkens BA, Busse R, Wagner A, Heitsch H, Linz W. The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett 1993;3:24-7.
21. Seyedi N, Xu XB, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995; 26:164-70.
22. Carey RM, Jin X-H, Wang Z-Q, Siragy HM. Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor. Acta Physiol Scand 2000;168:65-71.
23. Kuga T, Mohri M, Egashira K et al. Bradykinin-induced vasodilation of human coronary arteries in vivo: Role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol 1997;30:108-12.
24. Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990;182:395-6.
25. Werrmann JG, Cohen SM. Comparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postischemic working rat heart as studied by [31P] nuclear magnetic resonance. J Cardiovasc Pharmacol 1994;24:573-86.
26. Werrmann JG, Cohen SM. Use of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion. J Cardiovasc Pharmacol 1996;27:177-82.
27. Paz Y, Gurevitch J, Frolkis I et al. Effects of an angiotensin II antagonist on ischemic and nonischemic isolated rat hearts. Ann Thorac Surg 1998;65:474-9.
28. 2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996;94:3087-9.
29. Massoudy P, Becker BF, Gerlach E. Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol 1994;23:632-9.
30. Dörge H, Behrends M, Schulz R, Jalowy A, Heusch G. Attenuation of myocardial stunning by AT1 receptor antagonist candesartan. Basic Res Cardiol 1999;94:208-14.
31. van Gilst WH, de Graeff PA, Wesseling H, de Langen CDJ. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol 1986;8:722-8.
32. Ehring T, Baumgart D, Krajcar M, Hümmelgen M, Kompa S, Heusch G. Attenuation of myocardial stunning by the ACE-inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins, but not nitric oxide. Circulation 1994;90:1368-85.
33. Hohlfeld T, Strobach H, Schrör K. Stimulation of prostacyclin synthesis by defibrotide: Improved contractile recovery from myocardial "stunning". J Cardiovasc Pharmacol 1991;17:108-15.
34. Shimizu M, Wang Q-D, Sjôquist P-O, Rydén L. The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts. J Cardiovasc Pharmacol 1999;34:78-81.
35. Yoshiyama M, Kim S, Yamagishi H et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 1994;128:1-6.
36. 1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts. Eur J Pharmacol 1999;380:13-21.
37. Hoshida S, Yamashita N, Kuzuya T, Hori M. Differential effects of long-term renin-angiotensin system blockade on limitation of infarct size in cholesterol-fed rabbits. Atherosclerosis 2000;149:287-94.
38. Preckel B, Schlack W, Gonzalez M, Obal D, Bathel H, Thämer V. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol 2000;95:404-12.
39. Hartman JC, Hullinger TG, Wall TM, Shebuski RJ. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 1993;234:229-36.
40. Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995;27:883-92.
41. Diaz RJ, Wilson GJ. Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 1997;29:129-39.
42. Shimizu M, Wang Q-D, Sjöquist P-O, Ryden L. Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury. J Cardiovasc Pharmacol 1998;32:231-8.
43. Shimizu M, Wang Q-D, Sjöquist P-O, Rydén L. The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. Cardiovasc Drugs Ther 1999;13:347-53.
44. Shimizu M, Wang Q-D, Sjöquist P-O, Ryden L. Combination of a calcium antagonist, a lipid peroxidation inhibitor , and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs. J Cardiovasc Pharmacol 1999;34:512-7.
45. 2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998;32:1787-96.
46. Weidenbach R, Schulz R, Gres P, Behrends M, Post H, Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism. Br J Pharmacol 2000; 131:138-44.
47. Liu Y-H, Yang X-P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996;27:7-13.
48. Sladek T, Sladkova J, Kolar F et al. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 1996;31:568-76.
49. Richard V, Ghaleh B, Berdeaux A, Giudicelli J-F. Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs. Br J Pharmacol 1993;110:969-74.
50. Zhu B-Q, Sun Y-P, Sievers RE et al. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol 2000;35:787-95.
51. 2-receptor expression and IP3 receptor and PKCe proteins. JRAAS 2000;1:184-95.
52. Schwarz ER, Montino H, Fleischhauer J, Klues HG, vom Dahl J, Hanrath P. Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther 1997;11:687-95.
53. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.
54. Hartman JC, Kurc GM, Hullinger TG, Wall TM, Sheehy RM, Shebuski RJ. Inhibition of nitric oxide synthase prevents myocardial protection by ramipril. J Pharmacol Exp Ther 1994;3:1071-0.
55. Liang C-S, Gavras H, Black J, Sherman LG, Hood Jr. WB. Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation 1982;66:1249-55.
56. Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ. Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984;6:1043-7.
57. 1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol 1998;93 (Suppl 2):85-91.
58. Seyedi N, Xu XB, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70.
59. de Carvalho Frimm C, Sun Y, Weber KT. Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med 1997;129:439-46.
60. Gaussin V, Schneider MD. Surviving infarction one gene at a time. Decreased remodeling and mortality in engineered mice lacking the angiotensin II type 1A receptor. Circulation 1999;100:2043-1
61. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999;100:2093-9.
62. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 1993;25:1369-80.
63. Nishikimi T, Yamagishi H, Takeuchi K, Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in hypertensive rats. Cardiovasc Res 1995;29:856-61.
64. Schieffer B, Wirger A, Meybrunn M et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-82.
65. Kohya T, Yokoshiki H, Tohse N et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ Res 1995;76:892-9.
66. Gervais M, Richer C, Fornes P, de Gasparo M, Giudicelli J-F. Val̀sartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol 1999;13:635-45.
67. van Kats JP, Duncker DJ, Haitsma DB et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction. Role of tissue angiotensin II. Circulation 2000;102:1556-63.
68. Duncan A-M, James GM, Anastasopoulos F, Kladis A, Briscoe TA, Campbell DJ. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: Effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. J Pharmacol and Exper Ther 1999;289:295-303.
69. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac b-adrenergic receptors, and heart failure. Circulation 2000;101:1634-7.
70. 1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: Cellular mechanisms of action. J Card Fail 1998;4:325-32.
71. Spinale FG, de Gasparo M, Whitebread S et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure I. Effects on left ventricular performance and neurohormonal systems. Circulation 1997;96:2385-96.
72. 1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res 1998;38:631-45.
73. The Acute Infarction Ramipril Efficacy (AIRE) Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
74. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
75. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet 1997;349:747-52.
76. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
77. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Circulation 1999;100:1056-64.